Pharsight

1. Axid patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6930119	BRAINTREE	Liquid pharmaceutical composition	Jul, 2022 (1 year, 9 months ago)

Market Authorisation Date: 25 May, 2004

Treatment: NA

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg and 300 mg
15 mg/mL	14 May, 2008	1	18 Nov, 2009	17 Jul, 2022	Extinguished Eligible

Strength	Dosage	Availability
15MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7291324	BRAINTREE	Method of bowel cleansing	Oct, 2022 (1 year, 6 months ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jul 16, 2013

Market Authorisation Date: 24 September, 2007

Treatment: Gastrointestinal lavage indicated for cleansing of the colon as a preparation for colonoscopy in adults

Dosage: FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL	Discontinued
5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM	FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL	Discontinued